Conexiant
Login
  • Corneal Physician
  • Glaucoma Physician
  • New Retinal Physician
  • Ophthalmology Management
  • Ophthalmic Professional
  • Presbyopia Physician
  • Retinal Physician
The Ophthalmologist
  • Explore

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Anterior Segment
    • Glaucoma
    • Retina

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Cataract
    • Cornea
    • Glaucoma
    • Neuro-ophthalmology
    • Oculoplastics
    • Optometry
    • Pediatric
    • Retina
  • Business

    Business & Profession

    • Professional Development
    • Business and Entrepreneurship
    • Practice Management
    • Health Economics & Policy
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
Subscribe
Subscribe

False

Advertisement
The Ophthalmologist / Issues / 2026 / July / Smartphones Spot Ocular Malignancies
Research & Innovations Latest News

Smartphones Spot Ocular Malignancies

Could a smartphone-based AI system bring ocular oncology screening directly into the patient’s home?

7/2/2026 2 min read

Share

  • Full Article
  • Summary
  • Takeaways
  • Report
  • Quiz
  • Poll
  • Top Institutions

Clinical Report: Smartphones Spot Ocular Malignancies

Overview

A smartphone-based AI platform, CaptureTumor (CaT), was evaluated for early detection of ocular surface malignancies in a nationwide clinical trial. The system identified previously undiagnosed malignancies.

Background

Ocular surface malignancies are rare but can lead to significant morbidity if diagnosed late. Traditional screening methods often result in misdiagnosis as benign lesions, delaying necessary treatment. The integration of smartphone technology and AI may enhance early detection.

Data Highlights

MetricValue
AUC (smartphone testing)0.905
AUC (real-world screening)0.977
Sensitivity89.3%
Specificity95.9%
Histopathologically confirmed malignancies20

Key Findings

  • CaptureTumor (CaT) achieved an AUC of 0.977 in real-world screening.
  • The system identified 20 histopathologically confirmed malignancies, including 14 basal cell carcinomas and 6 malignant melanomas.
  • Nineteen of the identified malignancies were previously undiagnosed.
  • Patients identified through the app required fewer referrals to access specialist care compared to historical averages.
  • The app provided real-time guidance for optimal image capture to enhance diagnostic accuracy.

Clinical Implications

The use of smartphone-based AI for ocular malignancy screening may facilitate earlier diagnosis and treatment.

Conclusion

The CaptureTumor platform represents an advancement in the early detection of ocular surface malignancies.

Related Resources & Content

  1. JAMA Ophthalmology, 2026 -- Smartphone-Based Proactive Self-Screening for Ocular Surface Malignancies: A Nonrandomized Clinical Trial
  2. US Incidence and Demographics of Ocular Surface Squamous Neoplasia in the IRIS® Registry 2014–2021 - ScienceDirect
  3. Optometric Management — LEADING OFF
  4. Contact Lens Spectrum — May 2013 Online Photo Diagnosis
  5. Retinal Physician — Smartphone Technology for Fundus Photography
  6. Ophthalmology Management — Conjunctival tumor watch
  7. Optometric Management — LEADING OFF
  8. Contact Lens Spectrum — May 2013 Online Photo Diagnosis
  9. Retinal Physician — Smartphone Technology for Fundus Photography
  10. Smartphone-Based Proactive Self-Screening for Ocular Surface Malignancies: A Nonrandomized Clinical Trial | Trials | JAMA Ophthalmology | JAMA Network
  11. US Incidence and Demographics of Ocular Surface Squamous Neoplasia in the IRIS® Registry 2014–2021 - ScienceDirect

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.

Related Content

Newsletters

Receive the latest Ophthalmology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

False

Advertisement

Explore More in Ophthalmology

Dive deeper into the world of Ophthalmology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement
The Ophthalmologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Affiliations:

Specialties:

Areas of Expertise:

Contributions:

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: